ADAMTS2

Across TCGA pan-cancer cohorts, ADAMTS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAMTS2 data layer compared with 21 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ADAMTS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADAMTS2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ADAMTS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.508	0.902	.002	43	view →
PDAC	OS	Quartile	III,IV	0.240	1.000	.002	16	view →
LUAD	DFS	Quartile	All	0.363	0.833	.005	9	view →
LSCC	OS	Tertile	All	0.725	1.000	.023	4	view →
GBM	OS	Median	All	0.839	0.712	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAMTS2–CCRCC (DFS)

Open the CCRCC breakdown →